Treffer: Predicting carbapenem-resistant Pseudomonas aeruginosa infection risk using XGBoost model and explainability.
J Antimicrob Chemother. 2019 Feb 1;74(2):503-510. (PMID: 30376042)
Am J Emerg Med. 2020 Sep;38(9):1841-1846. (PMID: 32739855)
JAMA Netw Open. 2018 Oct 5;1(6):e183927. (PMID: 30646267)
Infect Control Hosp Epidemiol. 2006 Sep;27(9):893-900. (PMID: 16941312)
Eur J Clin Microbiol Infect Dis. 2024 Apr;43(4):627-640. (PMID: 38265603)
Lancet Microbe. 2023 Mar;4(3):e159-e170. (PMID: 36774938)
Front Microbiol. 2022 Jul 26;13:975616. (PMID: 35958138)
Infect Drug Resist. 2023 Nov 29;16:7351-7363. (PMID: 38050629)
Infect Drug Resist. 2022 Apr 29;15:2301-2314. (PMID: 35517901)
Antimicrob Agents Chemother. 2003 Mar;47(3):1096-100. (PMID: 12604547)
Mol Microbiol. 1996 Aug;21(4):713-24. (PMID: 8878035)
Int J Surg. 2023 Apr 01;109(4):1034-1036. (PMID: 36999801)
Antimicrob Agents Chemother. 2018 Mar 27;62(4):. (PMID: 29378722)
Antimicrob Agents Chemother. 2014 May;58(5):2626-37. (PMID: 24550343)
BMC Infect Dis. 2019 Dec 3;19(1):1028. (PMID: 31795953)
Antimicrob Resist Infect Control. 2019 Apr 25;8:68. (PMID: 31057792)
Clin Microbiol Infect. 2012 Mar;18(3):268-81. (PMID: 21793988)
J Transl Med. 2020 Dec 7;18(1):462. (PMID: 33287854)
Antimicrob Agents Chemother. 2024 May 2;68(5):e0166923. (PMID: 38564665)
Front Microbiol. 2024 Sep 05;15:1431154. (PMID: 39301190)
Emerg Microbes Infect. 2016 Mar 23;5:e27. (PMID: 27004762)
Comput Biol Med. 2021 Oct;137:104813. (PMID: 34481185)
Infect Drug Resist. 2023 Jan 19;16:337-346. (PMID: 36698726)
Annu Rev Microbiol. 2015;69:425-44. (PMID: 26488280)
0 (Carbapenems)
Weitere Informationen
The prevalence and spread of carbapenem-resistant Pseudomonas aeruginosa (CRPA) is a global public health problem. This study aims to identify the risk factors of CRPA infection and construct a machine learning model to provide a prediction tool for clinical prevention and control. A total of 1949 patients with P.aeruginosa health care-associated infections (HAIs) were enrolled in this study. A total of 89 patients with CRPA infection and 89 patients with CSPA infection were matched 1:1. LASSO regression was used to screen the variables, and the XGBoost model was established (136 cases in the training set and 60 cases in the test set). Shapley additive explain (SHAP) method was used to explain the importance of variables. The area under the ROC curve (AUC) and calibration curve were used to evaluate the performance of the model. There were 89 cases of CRPA infection, and the CRPA infection rate was 4.57%. Respiratory tract was the most common source of infection, and ICU and hematology department were the high-risk departments. The AUC value of the XGBoost machine learning model in the training set was 0.987 (95%CI: 0.974-1.000), and the AUC value in the test set was 0.862 (95%CI: 0.750-0.974). The clinical decision curve also showed good results of the model. SHAP results showed that ICU admission, duration of central venous catheterization, use of carbapenems and fluoroquinolones were important factors for predicting CRPA infection. The XGBoost machine learning model is helpful for the early prevention and screening of CRPA infection in medical institutions. Infection control and clinical departments should carry out effective prevention and control for high-risk factors to reduce the occurrence of CRPA infection.
(© 2025. The Author(s).)
Declarations. Competing interests: The authors declare no competing interests. Ethical approval: This study was approved by the Ethics Committee of the Second Hospital of Shanxi Medical University (2024YX-018). Because this study was retrospective, the institution waived the requirement for informed consent from patients. All study components were conducted in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and its later amendments